Introduction Chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for several hematological malignancies, yet patient-specific responses and toxicities remain hard to predict. Although multiple covariates and risk scores exist, their prognostic accuracy remains limited. Methods We prospectively measur...
Jonas Schadt, M. Rohnert, Paul Matthiensen et al.· Frontiers in Immunology· 0 citations
Anaplastic ependymoma is a rare and aggressive central nervous system malignancy for which effective systemic treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated intracranial activity in patients with HER2-...
D. Krex, I. Kerle, Arne Grey et al.· Molecular and Cellular Pedia...· 1 citation
Allogeneic hematopoietic cell transplantation (alloHCT) and chimeric antigen receptor T (CAR T)-cell therapy represent established therapeutic modalities for selected hematologic malignancies but are associated with substantial morbidity, high healthcare costs, and a considerable risk of severe complications, including...
M. Schneider, G. Mueller, S. Herbst et al.· Annals of Hematology· 0 citations
Relapsed or refractory acute myeloid leukemia (R/R AML) remains a therapeutic challenge, with standard high‑dose cytarabine-based salvage regimens achieving complete remission (CR) rates of around 50%. In the phase 1/2 RELAX trial, adding venetoclax (VEN) to high‑dose cytarabine and mitoxantrone (HAM) was considered sa...
A. Berdel, C. Röllig, C. Burkhard-Meier et al.· Haematologica· 0 citations
Macrophages are among the most abundant immune cells in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) and play a key role in regulating the immunosuppressive niche that facilitates tumor growth. Although recent three-dimensional (3D) culture systems using patient-derived materials have advanc...
Julius Thyen, V. A. Sioson, Daniel Haak et al.· npj Precision Oncology· 0 citations
SDRNAs are introduced as standalone regulatory effector molecules in healthy hematopoiesis and AML and proposed and characterized NUDT21, an important regulator of alternative polyadenylation and oncogenic gene expression, as a downstream target of sd3'-SNORD78 in AML.
R. Zinz, Christian Rohde, C. Pauli et al.· Leukemia· 0 citations
These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.
A. Tuettenberg, L. Ruhnke, J. Schlöder et al.· Transplantation and Cellular...· 0 citations
The main goal of the German National Strategy for GCT is to ensure patient access to advanced therapies while strengthening Germany’s position as an international hub for biomedical innovation.
Christian Gallus, F. Ayuk, P. Beckhove et al.· Human Gene Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
